New Data Demonstrate Efficacy of Investigational Drug for Episodic Cluster Headache, Migraine

Galcanezumab-gnlm (Emgality, Eli Lilly) demonstrated positive results in the treatment of patients with cluster headache and migraine, according to results from a phase 3 study and post-hoc analysis.  
 
Galcanezumab-gnlm is a monoclonal antibody designed to bind to and reduce the overactivity of calcitonin gene-related peptide, which is believed to play a role in migraine and cluster headaches.
 
The study included a 2-month treatment period evaluating the safety and efficacy of galcanezumab-gnlm (300 mg, once monthly) compared with a placebo in 106 patients with episodic cluster headache. Patients in the trial experienced an average of 17.5 cluster headache attacks per week at baseline.
 
According to the data, patients treated with galcanezumab-gnlm showed statistically significant differences in the reduction of weekly cluster headache attacks compared with patients treated with a placebo across weeks 1 to 3, which was the primary endpoint. Additionally, the safety and tolerability profile was consistent with previous studies that evaluated galcanezumab-gnlm for the prevention of migraine.

Related Coverage: Migraine Drug Demonstrates Efficacy in Patients with Multiple Treatment Failures
 
Eli Lilly also announced results from a post-hoc analysis that demonstrated the efficacy of galcanezumab-gnlm in patients with episodic and chronic migraine who had previously failed preventive treatment with onabotulinumtoxinA (Botox).
 
The analysis is based on data from the EVOLVE-1, EVOLVE-2, and REGAIN studies. The EVOLVE-1 and EVOLVE-2 studies are 6-month phase 3 trials evaluating 2 doses of galcanezumab-gnlm in patients with episodic migraine. The REGAIN study is a 3-month trial evaluating 2 doses of galcanezumab-gnlm in patients with chronic migraine.
 
According to the results, the researchers found that patients treated with both doses of galcanezumab-gnlm experienced a statistically significant reduction in the average number of monthly migraine headache days and at least a 50% reduction in the number of migraine headache days compared with those who received a placebo.
 
Galcanezumab-gnlm is currently under review by the FDA for the prevention of migraines in adults and a decision is expected by the end of September 2018, according to Lilly.
 
Reference
 
AHS 2018: Lilly’s Emgality (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed Botox (onabotulinumtoxinA) [news release]. Eli Lilly’s website.  https://investor.lilly.com/news-releases/news-release-details/ahs-2018-lillys-emgalitytm-galcanezumab-gnlm-significantly. Accessed June 28, 2018.
 
AHS 2018: Lilly Highlights Positive Phase 3 Results from Largest Controlled Preventive Trial in Episodic Cluster Headache [news release]. Eli Lilly’s website. https://investor.lilly.com/news-releases/news-release-details/ahs-2018-lilly-highlights-positive-phase-3-results-largest. Accessed June 28, 2018. 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Timolol eyedrops may have a potential role in managing acute migraine for some patients.
Allergan announced positive topline results from CGP-MD-01, a phase 2b/3 clinical trial of atogepant.
Investigative migraine therapy galcanezumab has reported more statistically significant benefits across multiple relevant outcomes.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$